Argent Biopharma Limited has released a press release.
U.S. In Vivo Study Supports ArtemiC Efficacy
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- RGT Signs Binding Term Sheet to Acquire AusCann Assets
- EU-GMP Cannabinoid API Supplied for Epilepsy in Slovenia
- Argent BioPharma Enters Germany - Europe's Largest Market
- Strategic Agreement to Enhance Cannabinoid Development
- Strategic Collaboration Agreement for Malta Facility
Later from Argent Biopharma
- Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition
- Appendix 4E and 2025 Annual Report
- Quarterly Activities/Appendix 4C Cash Flow Report
- A$11m Financing Facility to Complete Strategic Acquisition
- Streamlined Acquisition of AusCann Assets
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma